메뉴 건너뛰기




Volumn 110, Issue 10, 2007, Pages 3814-

Lenalidomide-induced severe hepatotoxicity

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CREATININE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LENALIDOMIDE; THALIDOMIDE; VINCRISTINE; WARFARIN;

EID: 36348939348     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-06-097758     Document Type: Letter
Times cited : (24)

References (3)
  • 1
    • 0024402108 scopus 로고
    • Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers
    • Chen TL, Vogelsang GB, Petty BG, et al. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos. 1989;17:402-405.
    • (1989) Drug Metab Dispos , vol.17 , pp. 402-405
    • Chen, T.L.1    Vogelsang, G.B.2    Petty, B.G.3
  • 2
    • 36348985356 scopus 로고    scopus 로고
    • Revlimid lenalidomide, package insert, Summit, NJ: Celgene Corporation; 2006
    • Revlimid (lenalidomide) [package insert]. Summit, NJ: Celgene Corporation; 2006.
  • 3
    • 28844496656 scopus 로고    scopus 로고
    • Lenalidomide: Patient management strategies
    • Hussein MA. Lenalidomide: patient management strategies. Semin Hematol. 2005;42:S22-S25.
    • (2005) Semin Hematol , vol.42
    • Hussein, M.A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.